CMS’ Off-Label Coverage Decision For Colorectal Cancer Drugs Could Include Registries
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services’ national coverage determination for oncologics, including Avastin and Erbitux, could be modeled on coverage for PET scans in Alzheimer’s patients, which includes trial registries. CMS expects to complete its coverage determination by Dec. 31.